Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
16,115 stopped studies · 89% state a reason
Over the 16,115 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT06572605 | External Beam Radiation Therapy in Combination With Talquetamab for the Treatment of… | Phase 1 / Phase 2 | suspended | Aug 27, 2024 | City of Hope Medical Center | pending amendment | Other (stated, no rule matched) |
| NCT06680661 | ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis | Phase 2 | suspended | Nov 8, 2024 | Leland Metheny | insufficient funding | Funding |
| NCT06704152 | BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant… | Phase 1 / Phase 2 | terminated | Nov 25, 2024 | BlueSphere Bio, Inc | Company Decision | Sponsor / business decision |
| NCT07566585 | Dose Finding Study to Evaluate the Safety of BSB-2002 in Relapsed or Refractory Acute… | Phase 1 | withdrawn | May 5, 2026 | BlueSphere Bio, Inc | Company Decision | Sponsor / business decision |
| NCT03917381 | GEN1046 Safety Trial in Patients With Malignant Solid Tumors | Phase 1 / Phase 2 | terminated | Apr 17, 2019 | Genmab | Genmab has decided to discontinue further clinical development of acasunlimab following strategic… | Safety / toxicity |
| NCT04947618 | Efficacy of Patient Management for Lymphoma Diagnosed at Nimes University Hospital From…(DVR-Lym-Nim) | — | terminated | Jul 1, 2021 | Centre Hospitalier Universitaire de Nīmes | The doctor retired and there's no one to take over the project | Other (stated, no rule matched) |
| NCT05188209 | A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Advanced Gastric… | Phase 2 | terminated | Jan 12, 2022 | Lepu Biopharma Co., Ltd. | Study terminated due to sponsor decision | Sponsor / business decision |
| NCT05685602 | CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic… | Phase 1 | suspended | Jan 17, 2023 | National Cancer Institute (NCI) | Drug Supply Issues | Drug supply |
| NCT06329570 | Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment… | Phase 1 / Phase 2 | suspended | Mar 26, 2024 | NaviFUS Corporation | FDA reviewing | Other (stated, no rule matched) |
| NCT06573294 | Trial to Assess the Safety and Antitumor Activity of GEN1057 in Malignant Solid Tumors | Phase 1 | terminated | Aug 27, 2024 | Genmab | Genmab has decided to terminate the GEN1057 program due to marginal anti-tumor activity not… | Other (stated, no rule matched) |
| NCT06888323 | Testing an Anti-cancer Radio-Active Immunotherapy Called Lintuzumab Ac225 in Patients… | Phase 1 | suspended | Mar 21, 2025 | National Cancer Institute (NCI) | Drug Supply Issues | Drug supply |
| NCT02129699 | Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy(SPLENDOUR) | Phase 3 | terminated | May 2, 2014 | ETOP IBCSG Partners Foundation | Completion of recruitment was not feasible as accrual was slower than anticipated. Even if a… | Enrollment / accrual |
| NCT03952598 | Studying the Biology of IDH-mutant Gliomas Via Longitudinal Observation of… | Phase 2 | suspended | May 16, 2019 | National Cancer Institute (NCI) | Study on hold pending possible updates with the team. | Other (stated, no rule matched) |
| NCT04544735 | Improving Women's Function After Pelvic Radiation | N/A | suspended | Sep 10, 2020 | Duke University | Study is suspended due to lack of funds. Will resume as soon as funding is secured. | Funding |
| NCT04926662 | Understanding Rural Patient and Provide Preferences for Mobile Lung Cancer Screening… | — | suspended | Jun 15, 2021 | Dartmouth-Hitchcock Medical Center | Study is paused while pre-aim 1 work is being done | Other (stated, no rule matched) |
| NCT06039384 | A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors… | Phase 1 | terminated | Sep 15, 2023 | Incyte Corporation | This was a strategic business decision. There were no safety concerns contributing to this decision. | Safety / toxicity |
| NCT06206746 | The REBALANCE Study - a Prospective, Multicenter, Randomized, Pivotal Study of the May… | N/A | terminated | Jan 16, 2024 | May Health | Business decision by sponsor to terminate the study | Sponsor / business decision |
| NCT02927249 | Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III… | Phase 3 | terminated | Oct 7, 2016 | Alliance for Clinical Trials in Oncology | DSMB review | Other (stated, no rule matched) |
| NCT04315233 | Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent…(CHARGE) | Phase 1 | terminated | Mar 19, 2020 | University of Utah | No accrual in one year | Enrollment / accrual |
| NCT05275868 | Study of MGY825 in Patients With Advanced Non-small Cell Lung Cancer | Phase 1 | terminated | Mar 11, 2022 | Novartis Pharmaceuticals | The trial was terminated due to a business decision and not as a result of any safety concerns | Safety / toxicity |
| NCT06050252 | Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine… | Phase 2 | suspended | Sep 22, 2023 | National Cancer Institute (NCI) | Other - evaluation of patients on first stage | Other (stated, no rule matched) |
| NCT06968988 | Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic… | Phase 1 | suspended | May 13, 2025 | Washington University School of Medicine | Protocol amendment | Other (stated, no rule matched) |
| NCT03145857 | A Study to Evaluate a New Way to Identify/Diagnose Tumours With Somatostatin Receptors… | Phase 1 / Phase 2 | terminated | May 9, 2017 | AHS Cancer Control Alberta | The market approved 68Ga-DOTATATE (NETSPOT(R)) is now approved for public funding in Alberta and is… | Drug supply |
| NCT04246177 | Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in… | Phase 3 | terminated | Jan 29, 2020 | Merck Sharp & Dohme LLC | Business Reasons | Sponsor / business decision |
| NCT05081882 | Reducing Tobacco-associated Lung Cancer Risk: A Randomized Clinical Trial of AB-free Kava | Phase 2 | terminated | Oct 18, 2021 | University of Florida | slow accrual | Enrollment / accrual |
| NCT05167409 | Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory… | Phase 2 | terminated | Dec 22, 2021 | University of Colorado, Denver | Accrual was terminated due to safety concerns | Safety / toxicity |
| NCT05813327 | Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma | Phase 1 | terminated | Apr 14, 2023 | Washington University School of Medicine | Polaris decided to close to accrual. | Enrollment / accrual |
| NCT06232044 | Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With… | Phase 1 / Phase 2 | suspended | Jan 30, 2024 | Alliance for Clinical Trials in Oncology | Enrollment to Dose Level 1 cohort has been met | Enrollment / accrual |
| NCT06405230 | Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular… | Phase 1 / Phase 2 | terminated | May 8, 2024 | GlaxoSmithKline | Operational challenges | Other (stated, no rule matched) |
| NCT06500377 | Comparing the Impact of Four Types of Meditation Practices for Relaxation in Cancer… | N/A | suspended | Jul 15, 2024 | City of Hope Medical Center | Accrual Goal Met | Enrollment / accrual |
| NCT06754761 | Human ADME Study of [14C]-Ceralasertib (AZD6738) and Absolute Bioavailability of… | Phase 1 | terminated | Jan 1, 2025 | AstraZeneca | A decision, based solely on business strategy, was taken to terminate study D533BC00002 on 22… | Sponsor / business decision |
| NCT07349771 | Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease… | Phase 2 | withdrawn | Jan 20, 2026 | Mayo Clinic | Sponsor declined to fund study due to inability to agree on IP. | Funding |
| NCT07414992 | A Study of Radiation Therapy and Cemiplimab With or Without Fianlimab In People With… | Phase 2 | withdrawn | Feb 17, 2026 | Memorial Sloan Kettering Cancer Center | The sponsor is no longer supporting the trial because they are no longer interested in studying the… | Other (stated, no rule matched) |
| NCT05700903 | Contributions to Hypertension With Androgen Deprivation Therapy(ARCH) | Phase 4 | terminated | Jan 26, 2023 | University of Colorado, Denver | Study completed | Other (stated, no rule matched) |
| NCT05930496 | Evaluating the Effects of an Exercise Intervention on the Gut Microbiota in Stage II-III… | N/A | terminated | Jul 5, 2023 | Fred Hutchinson Cancer Center | Terminated due to low accrual. | Enrollment / accrual |
| NCT06333678 | A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung Cancer… | Phase 2 | terminated | Mar 27, 2024 | Memorial Sloan Kettering Cancer Center | Study closed by Amgen due to lack of enrollment | Enrollment / accrual |
| NCT06487377 | IX001 TCR-T In the Treatment of Advanced Pancreatic Cancer and Colorectal Cancer Induced… | Phase 1 | withdrawn | Jul 5, 2024 | Shanghai Pudong Hospital | Study was stopped Sponsor discretion. No patients were dosed. | Other (stated, no rule matched) |
| NCT06581211 | Aromatherapy Oil Associated for Managing Anxiety and Pain During Bone Marrow Biopsy… | N/A | suspended | Sep 3, 2024 | City of Hope Medical Center | Accrual goal met | Enrollment / accrual |
| NCT06671912 | Testing Low Dose Tamoxifen for Invasive Breast Cancer, LoTam Trial(LoTam) | Phase 3 | suspended | Nov 4, 2024 | Alliance for Clinical Trials in Oncology | Amending protocol to increase sample size | Other (stated, no rule matched) |
| NCT06790966 | Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck…(VERSATILE-003) | Phase 3 | terminated | Jan 24, 2025 | PDS Biotechnology Corp. | The study is being discontinued solely based on financial constraints and is not related to the… | Safety / toxicity |
| NCT06873789 | A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid… | Phase 1 / Phase 2 | terminated | Mar 13, 2025 | Incyte Corporation | This was a strategic business decision. There were no safety concerns contributing to this decision. | Safety / toxicity |
| NCT06895681 | UCSF Biobank for Hereditary Cancers and Tumor-Associated Mutations | — | withdrawn | Mar 26, 2025 | University of California, San Francisco | IRB study closure | Other (stated, no rule matched) |
| NCT06929338 | xDRIVE in Metastatic Colorectal Cancer | — | withdrawn | Apr 16, 2025 | First Ascent Biomedical Inc. | Unable to finalize study agreements | Other (stated, no rule matched) |
| NCT01810913 | Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to… | Phase 2 / Phase 3 | suspended | Mar 14, 2013 | National Cancer Institute (NCI) | Other - Assessing accrual feasibility | Enrollment / accrual |
| NCT05279300 | A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas | Phase 1 | suspended | Mar 15, 2022 | CStone Pharmaceuticals | The sponsor is temporarily pausing the trial to evaluate existing clinical data for long-term… | Other (stated, no rule matched) |
| NCT05378763 | A Study of Poziotinib in Previously Treated Participants With Locally Advanced or…(PINNACLE) | Phase 3 | suspended | May 18, 2022 | Spectrum Pharmaceuticals, Inc | The study has not enrolled any patients. The study design is under discussion and will likely be… | Enrollment / accrual |
| NCT05438667 | TCR-T Cell Therapy on Advanced Solid Tumors | Early Phase 1 | terminated | Jun 30, 2022 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | In light of the impending acquisition of the project partner, Shanghai Bintie Biotechnology Co.,… | Sponsor / business decision |
| NCT06568172 | Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the… | Phase 3 | suspended | Aug 23, 2024 | National Cancer Institute (NCI) | Other - Other | Other (stated, no rule matched) |
| NCT02625961 | Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in… | Phase 2 | terminated | Dec 9, 2015 | Merck Sharp & Dohme LLC | Business Reasons | Sponsor / business decision |
| NCT04249843 | Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants… | Phase 1 | terminated | Jan 31, 2020 | MapKure, LLC | The study was terminated by the sponsor for reasons unrelated to safety. | Safety / toxicity |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 20 days agoSource updated Sep 10, 2026source: clinicaltrials